5-HT 2B receptor Inhibitors
1 drugsAbout 5-HT 2B receptor
The 5-HT2B receptor, also known as the serotonin 2B receptor, is a GPCR that binds serotonin and initiates intracellular signaling cascades. It plays a role in various physiological processes, though its precise functions are still being researched.
The 5-HT2B receptor has emerged as a target of interest for drug development, but currently there is no genetic evidence directly linking it to specific diseases.
There is one FDA-approved drug, BARHEMSYS, targeting 5-HT2B. It is a small molecule developed by ACACIA for one indication in the 'Other' therapeutic area.
Top 5-HT 2B receptor Drugs
ACACIA is the only company with an approved drug targeting 5-HT2B.
Low competition may present an opportunity, but also indicates potential challenges in the therapeutic area.
5-HT 2B receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets 5-HT 2B receptor, using small molecule modality.
Explore opportunities for novel modalities like antibodies or biologics to differentiate from existing treatments.
5-HT 2B receptor Clinical Trials 24 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on 5-HT 2B receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 6 | 6 | 0 | 0 | 100% |
| Phase 2 | 2 | 1 | 0 | 1 | 100% |
| Phase 3 | 6 | 3 | 1 | 2 | 75% |
| Phase 4 | 10 | 9 | 1 | 0 | 90% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
5-HT 2B receptor Drug Approval Timeline (2020 - 2020)
The first and most recent drug approval for 5-HT2B was BARHEMSYS in 2020.
Recent entry suggests growing interest, but lack of subsequent approvals may indicate developmental hurdles.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 18 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on 5-HT 2B receptor. A trial counts if an approved drug acting on 5-HT 2B receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.